Theracryf Plc

Stocks

Market Closed - London S.E. 11:35:00 2026-10-23 EDT			5-day change	1st Jan Change
0.1750 ^GBX	0.00%		0.00%	-12.50%

10-19	Cora Gold shareholder Eagle Eye restructures holding	AN
10-19	TheraCryf Completes Preclinical Safety Studies for Orexin-1 Addiction Drug Candidate	MT

Published on 04/27/2026 at 01:20 pm EDT - Modified on 06/11/2026 at 09:14 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the Theracryf Plc Investor Presentation [Operator Instructions]. Before we begin, I would like to submit the following

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

10-19	Cora Gold shareholder Eagle Eye restructures holding	AN
10-19	TheraCryf Completes Preclinical Safety Studies for Orexin-1 Addiction Drug Candidate	MT
10-02	Tooru gluten-free brand secures news listing	AN
09-28	Theracryf Plc Auditor Raises 'Going Concern' Doubt	CI
09-28	Theracryf Plc, 2026 Earnings Call, Sep 28, 2026
09-28	EARNINGS: US Solar Fund eyes "modest" fourth-quarter dividend	AN
09-28	Theracryf Plc Reports Earnings Results for the Full Year Ended March 31, 2026	CI
08-20	Theracryf's fund raise; Potter & Moore sales struggle	AN
05-14	EARNINGS & TRADING: Nexus Infrastructure first-half loss narrows	AN
05-14	Shares up as Strait of Hormuz talks lift mood	AN
05-14	WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down	AN
04-27	Theracryf Plc - Shareholder/Analyst Call
04-20	Catenai renews contract; Angus sees production uplift	AN
04-20	TheraCryf Advances Orexin-1 Addiction Program Toward Phase 1 Trials	MT
04-14	FTSE 100 flat as oil slips below USD100	AN

Duration

Period

Sector